Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on October 11, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print October 11, 2007, doi: 10.1161/ATVBAHA.107.148551
A more recent version of this article appeared on December 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/12/2548    most recent
ATVBAHA.107.148551v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nangaku, M.
Right arrow Articles by Miyata, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nangaku, M.
Right arrow Articles by Miyata, T.

Submitted on May 24, 2007
Accepted on September 26, 2007

A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia

Masaomi Nangaku ; Yuko Izuhara ; Shunya Takizawa ; Toshiharu Yamashita ; Yoshiaki Fujii-Kuriyama ; Osamu Ohneda ; Masayuki Yamamoto ; Charles van Ypersele de Strihou ; Noriaki Hirayama ; and Toshio Miyata *

From the Division of Nephrology and Endocrinology (M.N.), University of Tokyo School of Medicine, Japan; the Institute of Medical Sciences (Y.I., S.T., T.M.), Divisions of Nephrology, Hypertension, and Metabolism and of Neurology, Tokai University School of Medicine, Kanagawa, Japan; the Center for Tsukuba Advanced Research Alliance and Institute of Basic Medical Sciences (T.Y., O.O.), University of Tsukuba, Japan; the Center for Tsukuba Advanced Research Alliance (Y.F.-K.), University of Tsukuba, Japan; the Center for Tsukuba Advanced Research Alliance and JST-ERATO Environmental Response Project (M.Y.), University of Tsukuba, and the Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan; the Service de Nephrologie (C.v.Y.d.S.), Universite Catholique de Louvain, Brussels, Belgium; and the Basic Medical Science and Molecular Medicine (N.H.), Tokai University School of Medicine, Kanagawa, Japan.

* To whom correspondence should be addressed. E-mail: t-miyata{at}is.icc.u-tokai.ac.jp.

Objective—Hypoxia inducible factor (HIF) plays a pivotal role in the adaptation to ischemic conditions. Its activity is modulated by an oxygen-dependent hydroxylation of proline residues by prolyl hydroxylases (PHD).

Methods and Results—We discovered 2 unique compounds (TM6008 and TM6089), which inhibited PHD and stabilized HIF activity in vitro. Our docking simulation studies based on the 3-dimensional structure of human PHD2 disclosed that they preferentially bind to the active site of PHD. Whereas PHD inhibitors previously reported inhibit PHD activity via iron chelation, TM6089 does not share an iron chelating motif and is devoid of iron chelating activity. In vitro Matrigel assays and in vivo sponge assays demonstrated enhancement of angiogenesis by local administration of TM6008 and TM6089. Their oral administration stimulated HIF activity in various organs of transgenic rats expressing a hypoxia-responsive reporter vector. No acute toxicity was observed up to 2 weeks after a single oral dose of 2000 mg/kg for TM6008. Oral administration of TM6008 protected neurons in a model of cerebrovascular disease. The protection was associated with amelioration of apoptosis but independent of enhanced angiogenesis.

Conclusions—The present study uncovered beneficial effects of novel PHD inhibitors preferentially binding to the active site of PHD.


Key words: hypoxia • hypoxia inducible factor • structure based drug design • stroke • ischemia




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Schultz, V. Murthy, J. B. Tatro, and D. Beasley
Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1{alpha}-dependent mechanisms
Am J Physiol Lung Cell Mol Physiol, June 1, 2009; 296(6): L921 - L927.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Miyata and C. van Ypersele de Strihou
Translation of basic science into clinical medicine: novel targets for diabetic nephropathy
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1373 - 1377.
[Full Text] [PDF]